Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Saved in:
| Title: | Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. |
|---|---|
| Authors: | Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. abataller@mdanderson.org., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Urrutia S; Division of Oncology, Washington University in St. Louis, St. Louis, MO, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bouligny IM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Swaminathan M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roboz GJ; Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA., Savona M; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA., Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., McCloskey J; Hackensack University Medical Center, Hackensack, NJ, USA., Odenike O; The University of Chicago Pritzker School of Medicine, Chicago, IL, USA., Oganesian A; Taiho Oncology, Inc., Princeton, NJ, USA., Keer HN; Taiho Oncology, Inc., Princeton, NJ, USA., Azab M; Taiho Oncology, Inc., Princeton, NJ, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Mar 31; Vol. 15 (1), pp. 50. Date of Electronic Publication: 2025 Mar 31. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-025-01245-5 |
